TG Therapeutics Q4 EPS Forecast Increased by HC Wainwright

TG Therapeutics, Inc. (NASDAQ:TGTX) – HC Wainwright raised their Q4 2024 earnings estimates for TG Therapeutics in a report released on Monday, November 4th. HC Wainwright analyst E. White now expects that the biopharmaceutical company will earn $0.15 per share for the quarter, up from their previous estimate of $0.11. HC Wainwright currently has a “Buy” rating and a $55.00 target price on the stock. The consensus estimate for TG Therapeutics’ current full-year earnings is $0.13 per share.

Other research analysts have also issued reports about the stock. The Goldman Sachs Group upped their price objective on shares of TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday. TD Cowen assumed coverage on shares of TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 price objective for the company. Finally, B. Riley upped their target price on TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $37.67.

TG Therapeutics Price Performance

Shares of TG Therapeutics stock opened at $27.90 on Wednesday. The company has a market cap of $4.32 billion, a PE ratio of -278.97 and a beta of 2.19. The business has a 50 day moving average of $23.73 and a 200 day moving average of $20.36. TG Therapeutics has a 52 week low of $9.81 and a 52 week high of $28.41. The company has a quick ratio of 2.83, a current ratio of 3.58 and a debt-to-equity ratio of 0.58.

TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.01). The business had revenue of $83.90 million for the quarter, compared to the consensus estimate of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.65%. The company’s revenue for the quarter was down 49.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.73 EPS.

Institutional Trading of TG Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Marshall Wace LLP bought a new stake in TG Therapeutics in the second quarter worth $36,501,000. Hood River Capital Management LLC bought a new position in TG Therapeutics in the 1st quarter worth about $22,420,000. Principal Financial Group Inc. grew its position in TG Therapeutics by 1,549.4% during the 3rd quarter. Principal Financial Group Inc. now owns 772,188 shares of the biopharmaceutical company’s stock valued at $18,061,000 after purchasing an additional 725,371 shares during the last quarter. Point72 Asset Management L.P. bought a new stake in TG Therapeutics during the 2nd quarter valued at about $10,423,000. Finally, Assenagon Asset Management S.A. purchased a new position in TG Therapeutics in the second quarter worth about $8,698,000. Hedge funds and other institutional investors own 58.58% of the company’s stock.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.